163 related articles for article (PubMed ID: 35249879)
1. [Detection of DNA methylation of
Yin Y; Li H; Yang C; Zhang M; Huang X; Li M; Yang R; Zhang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jan; 42(1):123-129. PubMed ID: 35249879
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood.
Yang R; Pfütze K; Zucknick M; Sutter C; Wappenschmidt B; Marme F; Qu B; Cuk K; Engel C; Schott S; Schneeweiss A; Brenner H; Claus R; Plass C; Bugert P; Hoth M; Sohn C; Schmutzler R; Bartram CR; Burwinkel B
Int J Cancer; 2015 Apr; 136(8):1845-55. PubMed ID: 25213452
[TBL] [Abstract][Full Text] [Related]
3.
Li J; Yin Y; Huang H; Li M; Li H; Zhang M; Jiang C; Yang R
Epigenomics; 2023 Dec; 15(23):1257-1272. PubMed ID: 38126720
[No Abstract] [Full Text] [Related]
4. Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.
Park JL; Jeon S; Seo EH; Bae DH; Jeong YM; Kim Y; Bae JS; Kim SK; Jung CK; Kim YS
Thyroid; 2020 Feb; 30(2):192-203. PubMed ID: 31797753
[No Abstract] [Full Text] [Related]
5. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.
Iancu IV; Botezatu A; Plesa A; Huica I; Fudulu A; Albulescu A; Bostan M; Mihaila M; Grancea C; Manda DA; Dobrescu R; Vladoiu SV; Anton G; Badiu CV
Cancer Biomark; 2020; 28(2):255-268. PubMed ID: 32390600
[TBL] [Abstract][Full Text] [Related]
6. An Ep-ICD based index is a marker of aggressiveness and poor prognosis in thyroid carcinoma.
He HC; Kashat L; Kak I; Kunavisarut T; Gundelach R; Kim D; So AK; MacMillan C; Freeman JL; Ralhan R; Walfish PG
PLoS One; 2012; 7(9):e42893. PubMed ID: 23049733
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA methylation biomarker for the diagnosis of papillary thyroid carcinoma.
Hong S; Lin B; Xu M; Zhang Q; Huo Z; Su M; Ma C; Liang J; Yu S; He Q; Su Z; Li Y; Liu R; Guo Z; Lv W; Xiao H
EBioMedicine; 2023 Apr; 90():104497. PubMed ID: 36868052
[TBL] [Abstract][Full Text] [Related]
8. miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.
Qiao DH; He XM; Yang H; Zhou Y; Deng X; Cheng L; Zhou XY
Am J Otolaryngol; 2021; 42(2):102920. PubMed ID: 33454555
[TBL] [Abstract][Full Text] [Related]
9. DNA Methylation Status of HYAL1 in Malignant and Benign Thyroid Nodules.
Li M; Yin Y; Zhang M; Jiang C; Li H; Yang R
Horm Metab Res; 2023 Dec; 55(12):869-875. PubMed ID: 38040022
[TBL] [Abstract][Full Text] [Related]
10. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
11. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
12. Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.
Pan Q; Zhao J; Li M; Liu X; Xu Y; Li W; Wu S; Su Z
Carcinogenesis; 2020 Mar; 41(1):18-24. PubMed ID: 31560760
[TBL] [Abstract][Full Text] [Related]
13. A diagnostic model based on DNA methylation haplotype block characteristics for identifying papillary thyroid carcinoma from thyroid adenoma.
Xu D; Lai Y; Liu H; Li H; Feng N; Liu Y; Gong C; Zhang Y; Zhou J; Shen Y
Transl Res; 2024 Feb; 264():76-84. PubMed ID: 37863284
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA signature predicts survival in papillary thyroid carcinoma.
Chengfeng X; Gengming C; Junjia Z; Yunxia L
J Cell Biochem; 2019 Oct; 120(10):17050-17058. PubMed ID: 31099134
[TBL] [Abstract][Full Text] [Related]
16. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression.
Hosseinkhan N; Honardoost M; Blighe K; Moore CBT; Khamseh ME
J Endocrinol Invest; 2020 Jul; 43(7):911-923. PubMed ID: 31965517
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.
Liu J; Dong H; Yang Y; Qian Y; Liu J; Li Z; Guan H; Chen Z; Li C; Zhang K; Zhang Q; Cao W; Lv J
Future Oncol; 2018 Dec; 14(29):3015-3022. PubMed ID: 29987950
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of five miRNAs in papillary thyroid carcinomas.
Qiao DH; He XM; Deng X; Ji YC; Yang H; Cheng L; Zhou XY
J Clin Lab Anal; 2021 Sep; 35(9):e23907. PubMed ID: 34268792
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]